Codex

The Numbers

CI trades here because the market is treating it as a post-Medicare portfolio reset with a PBM overhang, not as a company with broken cash generation. The clean rerating metric is Evernorth-backed adjusted EPS growth, because GAAP earnings are still distorted by investment losses, sale accounting, and amortization.

Valuation Snapshot

The stock is back near its 2023 range even after adjusted EPS climbed close to $30 and free cash flow yield moved into double digits. That is the core setup: the market is discounting mix reset and PBM durability, not current cash generation.

Earnings Power

Revenue kept climbing as Evernorth became a larger part of the mix, but GAAP EPS became a bad anchor because VillageMD impairments, the Medicare divestiture, and amortization swamped the core trend. Adjusted EPS rose every year from FY2021 through FY2025, which is the earnings stream the market is really capitalizing.

Quarterly revenue kept stair-stepping higher through 2025, so the top-line damage from the Medicare exit is not showing up in the consolidated run-rate. The confidence break was the FY2024 Q4 miss; since then results have reverted to small beats, which is what the stock needs to keep rebuilding trust.

Cash Generation

Cash conversion is the strongest part of the CI case. Absolute free cash flow has stayed in an $8-10B band while buybacks cut diluted shares by more than one-fifth since FY2021, so per-share cash economics improved materially even without a straight-line FCF ramp.

Balance Sheet

This is not a stressed balance sheet for a company producing this much cash, but it is also not a clean book-value story. Goodwill and intangibles still sit well above common equity, so the downside case is more about execution and mix deterioration than near-term refinancing risk.

Critical Chart

The chart explains the stock. Evernorth is now the earnings engine and kept growing through FY2025, while Cigna Healthcare stepped down as the Medicare businesses left the portfolio. If Evernorth growth holds despite rebate-free investment and PBM policy pressure, today’s multiple looks too low; if it stalls, the discount probably persists.

Peer Valuation

CI screens as the cheapest name in the group on forward earnings despite ROE that holds up well against ELV, UNH, and MOH. That discount looks more like a skepticism tax on PBM durability and portfolio transition than a judgment that current earnings power is weak.

The numbers confirm that CI is still a high-cash, shareholder-friendly compounder at the per-share level. They contradict any view that reported GAAP volatility equals core earnings deterioration, because adjusted EPS, Evernorth profit, and free cash flow stayed resilient. Next quarter, watch Evernorth profit growth, cash conversion versus adjusted earnings, and whether the post-Medicare Cigna Healthcare base stabilizes without a new confidence break.